Drugs / ZL-1211
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05065710 | Jan 2022 → Mar 2024 | cancer or benign tumor | Zai Lab | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-06-01 | Zai Lab (Shanghai) Co., Ltd. | Results Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting zailaboratory.com ↗
the results showed ZL-1211 demonstrated a tolerable safety profile and preliminary antitumor effects. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-06-01 | Zai Lab (Shanghai) Co., Ltd. | Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting zailaboratory.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZL-1211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05065710 ↗ |
| Modality | Monoclonal antibody | “Here, we report that ZL-1211 is a mAb targeting CLDN18.2 engineered to promote enhanced antibody-dependent cellular cytotoxicity (ADCC) with the goal of achieving more potent...” PMID 36922936 ↗ Sep 2022 |
| Route | Intravenous | “This study is a Phase I/II, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetic (PK), pharmacodynamics...” NCT05065710 ↗ |
| Target | CLDN18 | “Here, we report that ZL-1211 is a mAb targeting CLDN18.2 engineered to promote enhanced antibody-dependent cellular cytotoxicity (ADCC) with the goal of achieving more potent...” PMID 36922936 ↗ Sep 2022 |